Skip to main content
. 2018 Jun 1;16:28. doi: 10.18332/tid/90668

Table 3.

Disclosure of conflicts of interest (COIs) according to the publication’s conclusions and the tendency to be favourable or not favourable to the use of e-cigarettes

Total No disclosure (code 0 ) Disclosed no COIs (code 1 ) Disclosed COIs for previous studies or for some authors (code 2 ) Disclosed no COIs, but acknowledge financial support by PTEC_COsa (code 3 ) Disclosed potential COIs (code 4 )

n n (%) n (%) n (%) n (%) n (%)
All publications 404 150 (37.1) 156 (38.6) 25 (6.2) 18 (4.5) 55 (13.6)
Conclusion
Favourable 79 11 (13.9) 23 (29.1) 14 (17.7) 2 (2.5) 29 (36.7)
Not favourable 93 33 (35.5) 53 (57.0) 0 (0.0) 2 (2.2) 5 (5.4)
Neutral/unclear 169 64 (37.9) 69 (40.8) 8 (4.7) 14 (8.3) 14 (8.3)
No conclusion 63 42 (66.7) 11 (17.5) 3 (4.8) 0 (0.0) 7 (11.1)
Publication tendencyb
Supports their use for harm reduction 83 24 (28.9) 23 (27.7) 11 (13.3) 2 (2.4) 23 (27.7)
Supports regulation 128 55 (43.0) 51 (39.8) 9 (7.0) 4 (3.1) 9 (7.0)
Supports their use for smoking cessation 71 18 (25.4) 18 (25.4) 10 (14.1) 2 (2.8) 23 (32.4)
Empirical studies 166 37 (22.3) 77 (46.4) 13 (7.8) 12 (7.2) 27 (16.3)
Conclusion
In favour 37 2 (5.4) 11 (29.7) 8 (21.6) 2 (5.4) 14 (37.8)
Not in favour 36 14 (38.9) 20 (55.6) 0 (0.0) 1 (2.8) 1 (2.8)
Neutral/unclear 91 20 (22.0) 46 (50.5) 5 (5.5) 9 (9.9) 11 (12.1)
No conclusion 2 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0)
Publication tendencyb
Supports their use for harm reduction 25 3 (12.0) 10 (40.0) 4 (16.0) 2 (8.0) 6 (24.0)
Supports regulation 44 13 (29.5) 23 (52.3) 5 (11.4) 2 (4.5) 1 (2.3)
Supports their use for smoking cessation 30 3 (10.0) 8 (26.7) 6 (20.0) 2 (6.7) 11 (36.6)
a

PTEC_COs: pharmaceutical (P), tobacco (T) and/or electronic cigarette (EC) companies.

b

Multiple responses were possible.